Roche pairs diabetes message and veterans' concert in 2nd annual iHeart partnership

Roche is again sponsoring iHeart's country music concert for veterans in November. This image is from last year's event. (Roche)

Roche is ready to rock with veterans in November as sponsor of iHeart’s military country music concert during National Diabetes Month.

The event at the Country Music Hall of Fame in Nashville spotlights both veterans and diabetes. Veterans Affairs reports one in four of its military patients have diabetes, compared with one in 10 nonveterans.

This is the second year Roche has sponsored the concert, but the Swiss drugmaker has been working with iHeartMedia for several years to help inform people with diabetes about their options, including Roche's own Accu-Chek testing supplies, Matt Logan, VP of marketing for Roche Diabetes Care, said in an email interview.

RELATED: Get smart? Novo Nordisk to roll connected insulin pens in deal with trio of tech partners

“Country music ranks high for people with diabetes, and the iHeartCountry One Night for Our Military reaches thousands of people who may be living with or know someone living with diabetes. To spread awareness surrounding this complex condition, attending a large-scale event … allows us to engage in the larger conversation,” he said.

The audience will include veterans from nearby Nashville military bases Fort Knox and Fort Campbell. The concert will be broadcast later, on Nov. 11, on iHeartRadio country stations across the country and on LiveXlive.com at 7 p.m.

RELATED: All in the diabetes family: Novo Nordisk addresses loved ones' hypoglycemia worries in new effort

As part of the effort, Roche is working with the Red Cross to donate comfort kits to troops deployed oversees.

Roche Diabetes Care, which includes Accu-Chek, is lagging last year's revenues, recently reporting a 2% year-over-year decline in sales through the first nine months of the year.

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?